REG-Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
Genmab's Phase 3 LiGeR-HN1 trial of petosemtamab plus pembrolizumab in first-line PD-L1+ recurrent/metastatic head and neck cancer met both primary endpoints at the first interim analysis. The combination cut the risk of death by 50% (OS HR 0.50, p<0.0001) and improved ORR (odds ratio 3.17) versus pembrolizumab alone, regardless of HPV status, with no new safety signals. Genmab plans to engage global regulatory authorities and will submit full results for presentation at a future medical meeting; it will host an investor update at 5:00 p.m.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 3
- Trial id
- NCT06525220
- Os p value
- <0.0001
- Orr p value
- <0.0001
- Orr odds ratio
- 3.17
- Os hazard ratio
- 0.50
- Risk of death reduction
- 50%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.